Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Merck
McKesson
Boehringer Ingelheim
Harvard Business School

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR CARBIDOPA, LEVODOPA AND ENTACAPONE


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Carbidopa, Levodopa And Entacapone

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT01766258 ↗ Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations Completed Orion Corporation, Orion Pharma Phase 2 2011-05-01 The primary objective of the study is to assess the efficacy, carbidopa dose response and safety of ODM-101, a new combination of levodopa, carbidopa and entacapone in the treatment of Parkinson's disease (PD) patients with end-of-dose motor fluctuations.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Carbidopa, Levodopa And Entacapone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00099268 ↗ Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy Completed Orion Corporation, Orion Pharma Phase 3 2004-09-01 The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.
NCT00099268 ↗ Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy Completed Novartis Pharmaceuticals Phase 3 2004-09-01 The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.
NCT00134966 ↗ A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa Completed Novartis Phase 3 2005-08-01 The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit than immediate release carbidopa/levodopa administered at the same levodopa dosage level of 100 mg three times a day (t.i.d.).
NCT00143026 ↗ Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States Completed Novartis Phase 4 2005-07-01 This study examines the effect of treatment of levodopa/entacapone on quality of life, as measured by the Parkinson's Disease-Questionnaire 8 (PDQ-8), in Parkinson's disease patients with no or minimal, non-disabling motor fluctuations.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Carbidopa, Levodopa And Entacapone

Condition Name

Condition Name for Carbidopa, Levodopa And Entacapone
Intervention Trials
Parkinson's Disease 11
Healthy 4
Parkinson Disease 3
Parkinson's Disease (PD) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Carbidopa, Levodopa And Entacapone
Intervention Trials
Parkinson Disease 16
Cocaine-Related Disorders 2
Disease 2
Nervous System Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Carbidopa, Levodopa And Entacapone

Trials by Country

Trials by Country for Carbidopa, Levodopa And Entacapone
Location Trials
United States 72
Canada 11
Italy 11
Germany 6
Czechia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Carbidopa, Levodopa And Entacapone
Location Trials
New York 6
Florida 5
California 5
Texas 4
Pennsylvania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Carbidopa, Levodopa And Entacapone

Clinical Trial Phase

Clinical Trial Phase for Carbidopa, Levodopa And Entacapone
Clinical Trial Phase Trials
Phase 4 5
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Carbidopa, Levodopa And Entacapone
Clinical Trial Phase Trials
Completed 18
Terminated 2
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Carbidopa, Levodopa And Entacapone

Sponsor Name

Sponsor Name for Carbidopa, Levodopa And Entacapone
Sponsor Trials
Novartis 8
Orion Corporation, Orion Pharma 3
Novartis Pharmaceuticals 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Carbidopa, Levodopa And Entacapone
Sponsor Trials
Industry 20
Other 6
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Harvard Business School
Merck
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.